ｌｉｐｏｓｏｍａｌ ｅｎｃａｐｓｕｌａｔｅｄ ｓｕｐｅｒｏｘｉｄｅ ｄｉｓｍｕｔａｓｅの川崎病に対する治療効果

Abstract

Since the increase in oxygen intermediate generation by neutrophils and its oxidative damages in the patients with Kawasaki disease were verified, superoxide dismutase (SOD) which quenches oxygen intermediates has been considered to be one of the beneficial therapy for Kawasaki disease. Liposomal encapsulated SOD (L-SOD) which A.M. Michelson developed was reported to be effective in various inflammatory disorders including those to whose pathogenesis an increase in oxygen intermediate generation has close correlation. We applied liposomal SOD injection in the treatment of six Kawasaki disease patients. The drug was effective in five of six patients. Fever faded away within four days after administration. Bilataral hyperemia of the bulbar conjunctiva, nonpurulent swelling of cervical lymph nodes and skin eruption were subsided in a few days after the injection. Formation of aneurysma of arteria coronaria was not observed in three patients out of four in whom coronaria arteria dilatation was confirmed. Unfortunately, one of four was not free of the formation of aneurysma. Liposomal SOD consists of some kinds of lipids and free SOD purified from bovine blood. It has advantages of long span (a harf life: 7.24 hr compared to 6 min of free SOD), better fixation and permeability to the tissues and organs, heat stability and organ specificity when compared to free SOD preparations. Since correlation of the formation of coronaria aneurysma in Kawasaki disease patients to the coagulatory activity activated by oxygen intermediates was reported, L-SOD seems to be applaisable for the treatment of Kawasaki disease and for the prevention of coronaria injury. The drug has the more advantages for its low or no toxicity.